OH-PROCTER-&-GAMBLE
This week, P&G Beauty convened a virtual meeting with leading global NGOs to discuss the role of the beauty industry in accelerating progress towards a more sustainable, inclusive and resilient future.
Until now, the industry has responded to consumer concerns over safety, quality, origin and sustainability with an array of claims – such as natural, organic or clean – many of which lack clear definitions and standards and are sometimes at odds with one another. The group made up of experts from various NGOs and Alex Keith, CEO, P&G Beauty, recognized that it is more vital than ever to look at these challenges as interconnected rather than individually. For the industry to become future-fit and to build business resilience, the group concluded that it must address systemic challenges through collective action, leveraging the best of science and protecting nature by purposefully bringing the two together.
P&G Beauty is addressing this through its P&G Responsible Beauty platform , a systems-thinking approach rooted in the connections and interdependence of five guiding principles: Quality & Performance; Safety; Sustainability; Transparency, and Equality & Inclusion. As part of the event, P&G Beauty shared the P&G Responsible Beauty 2030 goals (link ). One of the goals of P&G Responsible Beauty is openly sharing technologies, programs or processes that can help the beauty industry have a bigger, positive impact on the world. As a tangible first action to bring this goal to life the Company is making publicly available a comprehensive guide for the safe use of botanicals in beauty products (link ). The guide, incorporating learnings from over a decade of published research, provides formulators from small to large size beauty brands, with a robust safety approach to assess botanical ingredients and ensure their safe use in products.
The event, co-hosted by Women’s Wear Daily, was attended by media representatives from around the world, and featured P&G Beauty CEO Alex Keith and the P&G Responsible Beauty Advisory Council, an advisory group created more than a year ago to ensure P&G Beauty priorities are well informed by the most innovative, leading-edge thinking and experience. The Council is made up of representatives from Royal Botanic Gardens, Kew (a world leading authority on plant science); World Wildlife Fund (WWF); Rainforest Alliance; Skin Health Alliance; and the Roundtable on Sustainable Biomaterials.
“Making meaningful progress via responsible growth – growth rooted in systems thinking - requires partnership and collaboration,” said Alex Keith, CEO of P&G Beauty, “The P&G Responsible Beauty Advisory Council helps to ensure we are bringing external insights and experience into our decision-making, and applying systems thinking to our plans to ensure we consider the interdependencies of one choice on other critical areas.”
The panel discussion during the event covered a range of topics underscoring the extent to which human health and economic prosperity depend on a healthy, natural world, as well as how systems thinking can help the beauty industry navigate and understand today’s disruptions and provide solutions to build back better in a post-COVID world via a focus on responsible growth.
“Building business resilience in a way that supports a sustainable world, improves quality of life, respects human rights and protects the environment is possible,” said P&G Beauty’s Keith. "For beauty, this means going beyond environmental practices to address the interdependence of all aspects of product development and corporate behavior — all activities that affect the beauty consumer and the world in which we live.”
# # #
About the P&G Responsible Beauty Advisory Council Members:
Rainforest Alliance // Rainforest-alliance.org
The Rainforest Alliance works at the intersection of business, agriculture and forests to make “responsible business” the new normal, protecting forests and improving the lives of farmers and forest communities.
Roundtable on Sustainable Biomaterial // Rsb.org
The Roundtable on Sustainable Biomaterials (RSB) guides the responsible development and production of biomass, biofuels, and biomaterials through sustainability solutions, certification, and collaborative partnerships.
World Wildlife Fund // worldwildlife.org
For almost 60 years, the WWF has been protecting the future of nature. One of the world’s leading conservation organizations, WWF develops solutions to help communities and wildlife thrive.
Royal Botanic Gardens, Kew // kew.org
The global resource for plant and fungal research, the Royal Botanic Gardens, Kew uses their unparalleled expertise, botanical collections, and global partnerships to tackle the critical challenges facing humanity.
Skin Health Alliance // skinhealthalliance.org
The Skin Health Alliance collaborates with dermatologists, researchers and skin scientists to provide independent, scientifically based verification of the safety of beauty products, clinics, treatments, and services.
About P&G:
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.
For more information:
https://us.pg.com/responsible-beauty/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200610005452/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom